H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Larimar Therapeutics Analyst Ratings
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15
Leerink Partners Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
Larimar Therapeutics Analyst Ratings
Oppenheimer Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $26
Wedbush Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $22
H.C. Wainwright Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $15
Larimar Therapeutics Initiated at Buy by HC Wainwright & Co.
Larimar Therapeutics Price Target Announced at $14.00/Share by Jones Trading
JonesTrading Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $14
Larimar Therapeutics Analyst Ratings
Baird Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $16
Analysts Offer Insights on Healthcare Companies: 2seventy Bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)
Buy Rating Affirmed: Larimar Therapeutics' Strategic Expansion and Promising Clinical Progress
Buy Rating for Larimar Therapeutics Backed by Promising Gene Therapy Advances for Friedreich's Ataxia